IMPLQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IMPLQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
IPI Legacy Liquidation Co's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2023 was $-12.81 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2023 was $-70.11 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. IPI Legacy Liquidation Co's annualized ROC % for the quarter that ended in Sep. 2023 was -41.22%. IPI Legacy Liquidation Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -376.72%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield. IPI Legacy Liquidation Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -61.01%.
The historical data trend for IPI Legacy Liquidation Co's EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IPI Legacy Liquidation Co Annual Data | |||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | |||||
EBIT | -41.57 | -45.33 | -71.49 | -83.18 |
IPI Legacy Liquidation Co Quarterly Data | ||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
EBIT | Get a 7-Day Free Trial | -21.24 | -18.24 | -22.95 | -16.10 | -12.81 |
For the Biotechnology subindustry, IPI Legacy Liquidation Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, IPI Legacy Liquidation Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where IPI Legacy Liquidation Co's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-70.11 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IPI Legacy Liquidation Co (OTCPK:IMPLQ) EBIT Explanation
1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
IPI Legacy Liquidation Co's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:
ROC % (Q: Sep. 2023 ) | ||||||
= | NOPAT | / | Average Invested Capital | |||
= | Operating Income * ( 1 - Tax Rate % ) | / | ( (Invested Capital (Q: Jun. 2023 ) | + | Invested Capital (Q: Sep. 2023 )) | / count ) |
= | -51.244 * ( 1 - 0% ) | / | ( (121.716 | + | 126.938) | / 2 ) |
= | -51.244 | / | 124.327 | |||
= | -41.22 % |
where
Invested Capital | (Q: Jun. 2023 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 44.807 | - | 11.408 | - | ( 15.162 | - | max(0, 121.221 | - | 32.904 | + | 15.162 | )) |
= | 121.716 |
Invested Capital | (Q: Sep. 2023 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 35.073 | - | 9.451 | - | ( 0.239 | - | max(0, 124.743 | - | 23.427 | + | 0.239 | )) |
= | 126.938 |
Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.
2. Joel Greenblatt's definition of Return on Capital:
IPI Legacy Liquidation Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:
ROC (Joel Greenblatt) % | (Q: Sep. 2023 ) | ||||||
= | EBIT | / | Average of (Net fixed Assets | + | Net Working Capital) | ||
= | EBIT | / | Average of (Property, Plant and Equipment | + | Net Working Capital) | ||
Q: Jun. 2023 | Q: Sep. 2023 | ||||||
= | EBIT | / | ( ( (Property, Plant and Equipment + Net Working Capital) | + | (Property, Plant and Equipment + Net Working Capital) ) | / | count ) |
= | -51.244 | / | ( ( (8.386 + max(-53.941, 0)) | + | (7.817 + max(11.002, 0)) ) | / | 2 ) |
= | -51.244 | / | ( ( 8.386 | + | 18.819 ) | / | 2 ) |
= | -51.244 | / | 13.6025 | ||||
= | -376.72 % |
where Working Capital is:
Working Capital | (Q: Jun. 2023 ) | ||||||||||
= | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
= | (6.801 | + | 6.985 | + | 3.943) | - | (11.408 | + | 56.394 | + | 3.868) |
= | -53.941 |
Working Capital | (Q: Sep. 2023 ) | ||||||||||
= | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
= | (6.586 | + | 6.864 | + | 9.732) | - | (9.451 | + | 0 | + | 2.729) |
= | 11.002 |
When net working capital is negative, 0 is used.
Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.
3. It is also linked to Joel Greenblatt's definition of Earnings Yield:
IPI Legacy Liquidation Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:
Earnings Yield (Joel Greenblatt) % | = | EBIT (TTM) | / | Enterprise Value (Q: Sep. 2023 ) |
= | -70.11 | / | 114.918 | |
= | -61.01 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of IPI Legacy Liquidation Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Vivo Capital Fund Viii, L.p. | 10 percent owner | 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301 |
Michael Wayne Kalb | officer: CFO | 24 LUCILLE LANE, DIX HILLS NY 11746 |
Darren S Cline | director | 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140 |
Rajiv Amin | officer: VP, Controller & Interim CFO | C/O IMPEL PHARMACEUTICALS INC., 201 ELLIOTT AVENUE WEST, STE 260, SEATTLE WA 98119 |
Timothy S Nelson | director | 1024 BUBB ROAD, CUPERTINO CA 950144166 |
Adrian Adams | director, officer: COB, CEO and President | C/O AUXILIUM PHARMACEUTICALS, INC., 640 LEE ROAD, CHESTERBROOK PA 19355 |
Venbio Global Strategic Fund Ii L.p. | 10 percent owner | 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158 |
5am Opportunities I, L.p. | 10 percent owner | 501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
5am Opportunities I (gp), Llc | 10 percent owner | 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
5am Ventures V, L.p. | 10 percent owner | 2200 SAND HILL ROAD, SUITE 110, MENLO PARK CA 94025 |
Kkr Healthcare Strategic Growth Fund L.p. | 10 percent owner | C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019 |
Norwest Venture Partners Xiv, Lp | 10 percent owner | 525 UNIVERSITY AVENUE, SUITE 800, PALO ALTO CA 94301 |
Kkr Hcsg Gp Llc | 10 percent owner | C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019 |
5am Partners V, Llc | 10 percent owner | 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
Kkr Associates Hcsg L.p. | 10 percent owner | C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019 |
From GuruFocus
By sperokesalga sperokesalga • 06-15-2023
By GuruFocusNews GuruFocusNews • 06-19-2022
By PurpleRose PurpleRose • 07-11-2022
By sperokesalga sperokesalga • 04-26-2023
By PurpleRose PurpleRose • 07-19-2022
By sperokesalga sperokesalga • 05-10-2023
By GuruFocusNews GuruFocusNews • 06-28-2022
By sperokesalga sperokesalga • 04-12-2023
By sperokesalga sperokesalga • 03-17-2023
By GuruFocusNews GuruFocusNews • 06-21-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.